EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients

N/ACompletedNCT01942005

Andreas Arnold144 enrolled

Overview

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.

Study Type

OBSERVATIONAL

Enrollment

144

Conditions

Immunosuppression Neoplasm

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients in an immunosuppressive condition either by immunosuppressants or by HIV infection Exclusion Criteria: * written informed consent not given

Locations (1)

University Hospital Basel, Dermatology

Basel, Canton of Basel-City, Switzerland

Outcomes

Primary Outcomes

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

Time frame: 7 years

Secondary Outcomes

correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.

Time frame: 7 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.